Cover Image
Market Research Report

Kyorin Pharmaceutical Co Ltd - Product Pipeline Review - 2016

Published by Global Markets Direct Product code 251684
Published Content info 66 Pages
Delivery time: 1-2 business days
Price
Back to Top
Kyorin Pharmaceutical Co Ltd - Product Pipeline Review - 2016
Published: December 30, 2016 Content info: 66 Pages
Description

Summary:

Global Markets Direct's, 'Kyorin Pharmaceutical Co Ltd - Product Pipeline Review - 2016', provides an overview of the Kyorin Pharmaceutical Co Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kyorin Pharmaceutical Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Kyorin Pharmaceutical Co Ltd
  • The report provides overview of Kyorin Pharmaceutical Co Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Kyorin Pharmaceutical Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Kyorin Pharmaceutical Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Kyorin Pharmaceutical Co Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Kyorin Pharmaceutical Co Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Kyorin Pharmaceutical Co Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC08195CDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Kyorin Pharmaceutical Co Ltd Snapshot
    • Kyorin Pharmaceutical Co Ltd Overview
    • Key Facts
  • Kyorin Pharmaceutical Co Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Kyorin Pharmaceutical Co Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Kyorin Pharmaceutical Co Ltd - Pipeline Products Glance
    • Kyorin Pharmaceutical Co Ltd - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Kyorin Pharmaceutical Co Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Kyorin Pharmaceutical Co Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Kyorin Pharmaceutical Co Ltd - Drug Profiles
    • AX-10479 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibudilast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KCA-1490 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KRP-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KRP-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KRPAM-1977X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KRPAM-1977Y - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MN-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MTG-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • neramexane mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PDE4 for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tipelukast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vibegron - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Kyorin Pharmaceutical Co Ltd - Pipeline Analysis
    • Kyorin Pharmaceutical Co Ltd - Pipeline Products by Target
    • Kyorin Pharmaceutical Co Ltd - Pipeline Products by Route of Administration
    • Kyorin Pharmaceutical Co Ltd - Pipeline Products by Molecule Type
    • Kyorin Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action
  • Kyorin Pharmaceutical Co Ltd - Dormant Projects
  • Kyorin Pharmaceutical Co Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • KEA-0477
      • KRP-104
      • KRP-105
      • KRP-110
      • KRP-203
      • MK-0767
      • ranirestat
      • tipelukast
  • Kyorin Pharmaceutical Co Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Kyorin Pharmaceutical Co Ltd, Key Facts
  • Kyorin Pharmaceutical Co Ltd - Pipeline by Indication, 2016
  • Kyorin Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2016
  • Kyorin Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2016
  • Kyorin Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2016
  • Kyorin Pharmaceutical Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016
  • Kyorin Pharmaceutical Co Ltd - Out-Licensed Products in Pipeline, 2016
  • Kyorin Pharmaceutical Co Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Kyorin Pharmaceutical Co Ltd - Phase III, 2016
  • Kyorin Pharmaceutical Co Ltd - Phase II, 2016
  • Kyorin Pharmaceutical Co Ltd - Phase I, 2016
  • Kyorin Pharmaceutical Co Ltd - Preclinical, 2016
  • Kyorin Pharmaceutical Co Ltd - Discovery, 2016
  • Kyorin Pharmaceutical Co Ltd - Pipeline by Target, 2016
  • Kyorin Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2016
  • Kyorin Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2016
  • Kyorin Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action, 2016
  • Kyorin Pharmaceutical Co Ltd - Dormant Developmental Projects,2016
  • Kyorin Pharmaceutical Co Ltd - Discontinued Pipeline Products, 2016
  • Kyorin Pharmaceutical Co Ltd, Other Locations
  • Kyorin Pharmaceutical Co Ltd, Subsidiaries

List of Figures

  • Kyorin Pharmaceutical Co Ltd - Pipeline by Top 10 Indication, 2016
  • Kyorin Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2016
  • Kyorin Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2016
  • Kyorin Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2016
  • Kyorin Pharmaceutical Co Ltd - Out-Licensed Products in Pipeline, 2016
  • Kyorin Pharmaceutical Co Ltd - Pipeline by Top 10 Target, 2016
  • Kyorin Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2016
  • Kyorin Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2016
  • Kyorin Pharmaceutical Co Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top